Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Innovent Biologics Inc
(OP:
IVBXF
)
10.19
UNCHANGED
Streaming Delayed Price
Updated: 3:32 PM EST, Dec 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,910
Open
10.19
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
10.19
Today's Range
10.19 - 10.19
52wk Range
3.913 - 15.12
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
↗
August 24, 2024
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...
Via
Talk Markets
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
↗
July 27, 2024
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus...
Via
Talk Markets
Performance
YTD
+122.5%
+122.5%
1 Month
-14.7%
-14.7%
3 Month
-15.8%
-15.8%
6 Month
-4.1%
-4.1%
1 Year
+122.5%
+122.5%
More News
Read More
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
↗
July 06, 2024
Via
Talk Markets
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
↗
June 30, 2024
Via
Talk Markets
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
↗
May 25, 2024
Via
Talk Markets
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
↗
May 11, 2024
Via
Talk Markets
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
↗
April 06, 2024
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
↗
March 23, 2024
Via
Talk Markets
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
↗
March 09, 2024
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
↗
March 02, 2024
Via
Talk Markets
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
↗
February 24, 2024
Via
Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
↗
February 11, 2024
Via
Talk Markets
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
↗
December 31, 2023
Via
Talk Markets
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
↗
December 02, 2023
Via
Talk Markets
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
↗
November 04, 2023
Via
Talk Markets
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
↗
August 26, 2023
Via
Talk Markets
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
↗
July 08, 2023
Via
Talk Markets
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
↗
July 01, 2023
Via
Talk Markets
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
↗
June 17, 2023
Via
Talk Markets
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
↗
June 10, 2023
Via
Talk Markets
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
↗
May 13, 2023
Via
Talk Markets
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
↗
February 18, 2023
Via
Talk Markets
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
↗
February 04, 2023
Via
Talk Markets
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
↗
December 17, 2022
Via
Talk Markets
Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
↗
December 10, 2022
Via
Talk Markets
Frequently Asked Questions
Is Innovent Biologics Inc publicly traded?
Yes, Innovent Biologics Inc is publicly traded.
What exchange does Innovent Biologics Inc trade on?
Innovent Biologics Inc trades on the OTC Traded
What is the ticker symbol for Innovent Biologics Inc?
The ticker symbol for Innovent Biologics Inc is IVBXF on the OTC Traded
What is the current price of Innovent Biologics Inc?
The current price of Innovent Biologics Inc is 10.19
When was Innovent Biologics Inc last traded?
The last trade of Innovent Biologics Inc was at 12/22/25 03:32 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.